| 货号 | AF1016-SP |
| 别名 | CD110 antigen; CD110; c-Mpl; MPL; MPLV; Myeloproliferative leukemia protein; myeloproliferative leukemia virus oncogene; Proto-oncogene c-Mpl; thrombopoietin receptor; TPO-R; TPORMPLV | 全称 | Thrombopoietin Receptor |
| 反应种属 | Human |
| 应用 | Western Blot(0.1 µg/mL) |
| 目标/特异性 | Detects human Thrombopoietin R/Tpo R in direct ELISAs and Western blots. In direct ELISAs and Western blots, less than 1% cross‑reactivity with recombinant human Epo R is observed. |
| 使用方法 | Western Blot: 0.1 µg/mL Neutralization: Measured by its ability to neutralize Thrombopoietin/Tpo-induced proliferation in the MO7e human megakaryocytic leukemic cell line. Avanzi, G. et al. (1988) Br. J. Haematol. 69:359. The Neutralization Dose (ND50) is typically 0.5‑2.5 µg/mL in the presence of 10 ng/mL Recombinant Human Thrombopoietin/Tpo. |
| 来源 | Polyclonal Goat IgG |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 4352 (Human); 17480 (Mouse) |
| 应用文献 | |
| R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. BMP4 regulation of human megakaryocytic differentiation is involved in thrombopoietin signaling. | |
| 纯化方式 | Antigen Affinity-purified |
| 免疫原 | Mouse myeloma cell line NS0-derived recombinant human Thrombopoietin R/Tpo R Gln26-Tyr423 Accession # P40238 |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Human |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 背景 | Thrombopoietin receptor (Tpo R), also known as myeloproliferative leukemia protein (c-mpl), is a 95 kDa type I transmembrane protein that is a member of the type I cytokine receptor family within the hematopoietin/cytokine receptor superfamily (1‑4). The 635 amino acid (aa) full-length human Tpo R contains a 25 aa signal sequence, a 466 aa extracellular domain with a ligand binding domain and two fibronectin type III domains, a transmembrane (TM) domain and a cytoplasmic domain. The extracellular domain of human Tpo R shares 78%, 76%, 81%, 82% and 80% aa identity with mouse, rat, bovine, canine and equine Tpo R, respectively. Humans produce three distinct mRNA species; a P-form, a K-form, and a truncated form (Mpl-tr) lacking a TM domain (3‑7). The P-form encodes the full-length receptor. The Mpl-tr form, which is expressed in both human and mouse, is intracellular and targets the P-form for degradation (5, 6). The 579 aa K-form has an alternate cytoplasmic domain, but does not dimerize with, or inhibit, the P-form (7). Thrombopoietin (Tpo) is a key regulator of megakaryocytopoiesis, thrombopoiesis and hematopoietic stem cell self-renewal, as reflected by expression of the Tpo R on megakaryocytes, platelets and hematopoietic progenitors (2, 8). Receptor dimerization occurs upon Tpo binding and initiates signaling through the Ras/MAP and JAK/STAT pathways (1, 2). Internalization and degradation of Tpo following Tpo R binding serves to downregulate circulating Tpo (9). Tpo R expressed at low levels on endothelial cells does not appear to contribute to regulation of Tpo (10). Inactivating mutations of Tpo R cause thrombocytopenia, and absence of functional Tpo R is lethal in humans, but not mice. Other mutations, including an activating change in the TM domain, can cause thrombocytosis (11, 12). |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|
Cell Proliferation Induced by Thrombopoietin/Tpo and Neutralization by Human Thrombopoietin R/Tpo R Antibody. Recombinant Human Thrombopoietin/Tpo (Catalog # 288-TP) stimulates proliferation in the MO7e human megakaryocytic leukemic cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human Thrombopoietin/Tpo (10 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human Thrombopoietin R/Tpo R Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1016). The ND50 is typically 0.5‑2.5 µg/mL. |
